Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>Key points:</p><ul>
<li>Energy names are showing signs of bottoming with the recent uptick in crude, and weakness in the U.S. dollar</li>
<li>REITs are continuing to firm up as rates have plateaued</li>
<li>Biotech stocks are continuing to show leadership characteristics</li>
</ul><p>Charts highlighted: AFI, ODP, SPWH, CVS, KMB, THS, CHK, KMI, RRC, AXS, ESS, KIM, APTS, KRG, REGN, NERV, NSTG, RARX, AYI, CFX, AXL, PAH, FNSR, TRUE, ALK, HA, SAVE, and PEGI</p>

Key points:
Energy names are showing signs of bottoming with the recent uptick in crude, and weakness in the U.S. dollar
REITs are continuing to firm up as rates have plateaued
Biotech stocks are continuing to show leadership characteristics
Charts highlighted: AFI, ODP, SPWH, CVS, KMB, THS, CHK, KMI, RRC, AXS, ESS, KIM, APTS, KRG, REGN, NERV, NSTG, RARX, AYI, CFX, AXL, PAH, FNSR, TRUE, ALK, HA, SAVE, and PEGI

Technically Attractive U.S. Stocks for Value Investors

United States

Enovis Corporation operates as a medical technology company. The Company develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Enovis serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Enovis (ENOV US)

Technically Attractive U.S. Stocks for Value Investors

Key points: Energy names are showing signs of bottoming with the recent uptick in crude, and weakness in the U.S. dollar REITs are continuing to...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)